March 28, 2012
Drug Candidates Derailed in Case of Mistaken Identity
Scott Kaufmann fears a rush to judgement. He studies DNA-repair proteins called poly(ADP-ribose) polymerases, or PARPs, that have shown promise as targets for anticancer drugs. Until early last year, compounds that inhibit PARPs were the next big thing in cancer drug development (see ‘Suspect class’). Then, a leading candidate PARP inhibitor called iniparib failed a […]
Tags: anticancer drugs, PARPs, Scott Kaufmann